These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27559936)

  • 1. Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors.
    Wu YJ; Guernon J; Shi J; Marcin L; Higgins M; Rajamani R; Muckelbauer J; Lewis H; Chang C; Camac D; Toyn JH; Ahlijanian MK; Albright CF; Macor JE; Thompson LA
    J Med Chem; 2016 Sep; 59(18):8593-600. PubMed ID: 27559936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors.
    Wu YJ; Guernon J; Rajamani R; Toyn JH; Ahlijanian MK; Albright CF; Muckelbauer J; Chang C; Camac D; Macor JE; Thompson LA
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5729-5731. PubMed ID: 27816517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.
    Pettus LH; Bourbeau MP; Bradley J; Bartberger MD; Chen K; Hickman D; Johnson M; Liu Q; Manning JR; Nanez A; Siegmund AC; Wen PH; Whittington DA; Allen JR; Wood S
    J Med Chem; 2020 Mar; 63(5):2263-2281. PubMed ID: 31589043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding Burden.
    Anan K; Iso Y; Oguma T; Nakahara K; Suzuki S; Yamamoto T; Matsuoka E; Ito H; Sakaguchi G; Ando S; Morimoto K; Kanegawa N; Kido Y; Kawachi T; Fukushima T; Teisman A; Urmaliya V; Dhuyvetter D; Borghys H; Austin N; Van Den Bergh A; Verboven P; Bischoff F; Gijsen HJM; Yamano Y; Kusakabe K
    ChemMedChem; 2019 Nov; 14(22):1894-1910. PubMed ID: 31657130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).
    Cheng Y; Judd TC; Bartberger MD; Brown J; Chen K; Fremeau RT; Hickman D; Hitchcock SA; Jordan B; Li V; Lopez P; Louie SW; Luo Y; Michelsen K; Nixey T; Powers TS; Rattan C; Sickmier EA; St Jean DJ; Wahl RC; Wen PH; Wood S
    J Med Chem; 2011 Aug; 54(16):5836-57. PubMed ID: 21707077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
    May PC; Dean RA; Lowe SL; Martenyi F; Sheehan SM; Boggs LN; Monk SA; Mathes BM; Mergott DJ; Watson BM; Stout SL; Timm DE; Smith Labell E; Gonzales CR; Nakano M; Jhee SS; Yen M; Ereshefsky L; Lindstrom TD; Calligaro DO; Cocke PJ; Greg Hall D; Friedrich S; Citron M; Audia JE
    J Neurosci; 2011 Nov; 31(46):16507-16. PubMed ID: 22090477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
    Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
    J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition.
    Schelle J; Häsler LM; Göpfert JC; Joos TO; Vanderstichele H; Stoops E; Mandelkow EM; Neumann U; Shimshek DR; Staufenbiel M; Jucker M; Kaeser SA
    Alzheimers Dement; 2017 Jun; 13(6):701-709. PubMed ID: 27750032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides.
    Rueeger H; Lueoend R; Rogel O; Rondeau JM; Möbitz H; Machauer R; Jacobson L; Staufenbiel M; Desrayaud S; Neumann U
    J Med Chem; 2012 Apr; 55(7):3364-86. PubMed ID: 22380629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.
    Butler CR; Brodney MA; Beck EM; Barreiro G; Nolan CE; Pan F; Vajdos F; Parris K; Varghese AH; Helal CJ; Lira R; Doran SD; Riddell DR; Buzon LM; Dutra JK; Martinez-Alsina LA; Ogilvie K; Murray JC; Young JM; Atchison K; Robshaw A; Gonzales C; Wang J; Zhang Y; O'Neill BT
    J Med Chem; 2015 Mar; 58(6):2678-702. PubMed ID: 25695670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid β-peptides.
    Rueeger H; Lueoend R; Machauer R; Veenstra SJ; Jacobson LH; Staufenbiel M; Desrayaud S; Rondeau JM; Möbitz H; Neumann U
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5300-6. PubMed ID: 23981898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain.
    Zhang L; Chen L; Dutra JK; Beck EM; Nag S; Takano A; Amini N; Arakawa R; Brodney MA; Buzon LM; Doran SD; Lanyon LF; McCarthy TJ; Bales KR; Nolan CE; O'Neill BT; Schildknegt K; Halldin C; Villalobos A
    J Med Chem; 2018 Apr; 61(8):3296-3308. PubMed ID: 29356535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
    Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
    Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Identification of Biochanin A as a Potent and Selective β-Site App-Cleaving Enzyme 1 (Bace1) Inhibitor.
    Youn K; Park JH; Lee J; Jeong WS; Ho CT; Jun M
    Nutrients; 2016 Oct; 8(10):. PubMed ID: 27754406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 7-tetrahydropyran-2-yl chromans: β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloid β-protein (Aβ) in the central nervous system.
    Thomas AA; Hunt KW; Volgraf M; Watts RJ; Liu X; Vigers G; Smith D; Sammond D; Tang TP; Rhodes SP; Metcalf AT; Brown KD; Otten JN; Burkard M; Cox AA; Do MK; Dutcher D; Rana S; DeLisle RK; Regal K; Wright AD; Groneberg R; Scearce-Levie K; Siu M; Purkey HE; Lyssikatos JP; Gunawardana IW
    J Med Chem; 2014 Feb; 57(3):878-902. PubMed ID: 24397738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
    Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
    J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor.
    Cumming JN; Smith EM; Wang L; Misiaszek J; Durkin J; Pan J; Iserloh U; Wu Y; Zhu Z; Strickland C; Voigt J; Chen X; Kennedy ME; Kuvelkar R; Hyde LA; Cox K; Favreau L; Czarniecki MF; Greenlee WJ; McKittrick BA; Parker EM; Stamford AW
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2444-9. PubMed ID: 22390835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and discovery of C2-fluoroalkyl iminothiazine dioxides as BACE inhibitors.
    Taoka BM; Wu WL; Hao J; Dolmaski M; Wang H; Levorse D; Orth P; Hyde LA; Smith B; Michener MS; Kennedy ME; Parker EM; Cumming JN
    Bioorg Med Chem Lett; 2022 Jan; 56():128463. PubMed ID: 34838652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.